ProCE Banner Activity

ExpressPoints: Educating Providers and Patients to Optimize the Use of Targeted Oral Therapies for HR+/HER2- Breast Cancer

Slideset Download

Gain key clinical insights fast, with this short slideset from CCO on the optimal use of CDK4/6 and PIK3CA inhibitors for patients with HR+/HER2 breast cancer.  

Resources for your patients: https://www.smartpatients.com/resources/cco-breast-cancer

Released: March 09, 2021

Expiration: March 08, 2022

No longer available for credit.

Share

Faculty

Matthew P. Goetz

Matthew P. Goetz, MD

Professor of Oncology and Pharmacology
Director, Mayo Breast Cancer SPORE
Co-PI, Womens Cancer Program
Department of Medical Oncology
Mayo Clinic
Rochester, Minnesota

Sara Hurvitz

Sara Hurvitz, MD

Assistant Professor of Medicine
Director, Breast Oncology Program
Division of Hematology-Oncology
Department of Internal Medicine
David Geffen School of Medicine at UCLA
Los Angeles, California

Supporters

Supported by an educational grant from

Lilly

Partners

Smart Patients

ProCE Banner

Faculty Disclosure

Primary Author

Matthew P. Goetz, MD

Professor of Oncology and Pharmacology
Director, Mayo Breast Cancer SPORE
Co-PI, Womens Cancer Program
Department of Medical Oncology
Mayo Clinic
Rochester, Minnesota

Sara Hurvitz, MD

Assistant Professor of Medicine
Director, Breast Oncology Program
Division of Hematology-Oncology
Department of Internal Medicine
David Geffen School of Medicine at UCLA
Los Angeles, California